XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.2
Inventory
6 Months Ended
Jun. 30, 2022
Inventory  
Inventory

Note 6.     Inventory

Our inventory balance consists of the following (in thousands):

June 30,

December 31,

    

2022

    

2021

 

Raw materials

$

22,371

$

1,275

Work-in-process

36,317

39,895

Finished goods

 

35,440

 

15,768

Total inventory

$

94,128

$

56,938

Inventories, stated at the lower of cost and net realizable value, consist of raw materials, work in process and finished goods. At June 30, 2022, $54.5 million of inventory was classified as current on the condensed consolidated balance sheet as we expect this inventory to be consumed for commercial use within the next twelve months. At June 30, 2022, $39.6 million of inventory was classified as non-current on the condensed consolidated balance sheet as we did not expect this inventory to be consumed for commercial use within the next twelve months. We obtain some inventory components from a limited number of suppliers due to technology, availability, price, quality or other considerations. The loss of a supplier, the deterioration of our relationship with a supplier, or any unilateral violation of the contractual terms under which we are supplied components by a supplier could adversely affect our total revenues and gross margins.

We capitalize inventory after U.S. Food and Drug Administration (FDA) approval as the related costs are expected to be recoverable through the commercialization of the product.  Costs incurred prior to FDA approval are recorded as research and development expense in our statements of operations. At June 30, 2022, inventory with approximately $66.0 million of product costs incurred prior to FDA approval had not yet been sold. We expect to sell the pre commercialization inventory over the next 30 months and, as a result, cost of product revenues will reflect a lower average per unit cost of materials.